Faculty Profile
Dr. Kirmani
Saeeda Kirmani, M.D.
Clinical Professor of Medicine
University of California, San Diego
Veterans Administration Medical Center
Office Address:
Division of Hematology-Oncology
Veterans Administration Medical Center
3350 La Jolla Village Drive, MC-9111E
San Diego, CA 92161
skirmani@ucsd.edu
Office: (858) 552-3356
FAX: (858) 552-7485
Education and Training
| Fellow of Science | Premedical, Punjab University, Pakistan | 1968 |
| MBBS | Punjab University, Pakistan | 1974 |
| Intern/Resident | University of Maryland, Baltimore | 1975-1978 |
| Fellow Hematology-Oncology | Letterman Army Medical Center, San Francisco | 1979-7982 |
| Training in Hematopathology | Armed Forces Institute of Pathology, Washington DC | 1980 |
Research Interests
Dr. Kirmani is a clinical investigator conducting a wide range of phase I-III cancer trials primarily at the San Diego Veterans Hospital. She is the VA-responsible investigator for all cancer cooperative group studies including CALGB, RTOG and VA-CORNET. In addition, she is a clinical investigator for a number of industry-sponsored, as well as investigator-initiated studies.
Publications
Plaxe SC, Braly PS, Freddo JL, McClay E, Christen RD, Kirmani S, Kim S, Heath DH, Howell SB. Phase I and pharmacokinetic study of intraperitoneal ormaplatin. Gyn Oncol, 51:72-77, 1993
Bonetti A, Howell SB, McClay E, Kirmani S, Goel R, Plaxe S, Braly P, Kim S. High-dose beweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity. Gyn Oncol, 49:318-324, 1993.
Kirmani S, Braly PS, McClay EF, Satlstein SS, Plaxe SC, Kim S, Cates C, Howell SB. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol, 54:338-344, 1994.
McClay EF, Goel R, Andrews P, Gorelick S, Kirmani S, Kim S, Braly P, Plaxe S, Hoff S, Alcaraz J. Howell SB. A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. Brit J Cancer, 68:783-788, 1993.
McClay EF, Braly PD, Kirmani S, Plaxe SC, McClay ME, Wilus L, Kim S, Howell SB. A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophase colony stimulating factor support inpatients with intra-abdominal malignancies. Cancer, 74:664-669.
Plaxe S, Freddo J, Kim S, Kirmani S, McClay E, Christen R, Braly P, Howell SB. Phase I trial of cisplatin in combination with gluthione. Gynecol Oncol, 55:82-86, 1994.
McClay E, Braly P, Kirmani S, McClay E, Christen R, Braly P, Howell SB. Phase I trial of cisplatin in combination with glutathione. Gynecol Oncol, 55:82-86, 1994.
Weisman RA, Christen R, Los, G, Jones V, Kerber C, Seagren S, Glassmeyer S, Orloff LA, Wong, Kirmani S, Howell SB. Phase I trial of retinoic acid and dis-platinum for advanced squamous cell cancer of the head and next based on experimental evidence of drug synergism. Otolaryngology-Head and Neck Surgery, 118(5), 597-602, May 1998.
Aebi S, Schnider YW, Los G. Heath DD, Darrah D. Kirmani S, McClay EF, D’Agostino H, Plax SC, Fink D, de las Alas MM, Howell SB, Christen RD. A Phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel, Cancer Chemotherapy and Pharmacology 44(3):259-65, 1999.
Los G, Benbatoul K, Gateley DP, Barton R, Christen R, Robbins KT, Vicario D. Kirmani S, Orloff LA, Weisman R, Howell SB. Quantitation of the change in GADD153 messenger RNA level as a molecular marker for tumor response in head and neck cancer. Clinical Cancer Research 5(7):1710-8, 1999.
De las Alas MM, Christen RD, Gateley DP, Weiner DE, Benbatoul K, Kirmani S, D’Agostino HR, Plaxe SC, Darrah D, McClay EF, Aebi S, Howell SB, Los G. Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. Cancer Chemotherapy and Pharmacoloty, 45(5):381-8, 2000.
